ImmunOs Therapeutics develops novel human immunomodulatory proteins focused on innate immunity to treat serious disease. Immunomodulation refers to a process that alters the immune system response. It was from iosH, ImmunOs Therapeutics’ own platform to develop proteins, that the company’s lead product candidate, iosH2, for tumor treatment emerged.
Following a successful Series A financing round that raised 15 million Swiss francs, ImmunOs plans to complete the first clinical trials on iosH2 and develop the platform further, according to a statement. The financing will help to broaden the platform for the development of treatments for cancer and autoimmune disease, and to advance additional preclinical programs.
The financing round was led by the Basel venture capital company BioMedPartners and Pfizer’s venture capital arm Pfizer Ventures. In conjunction with the financing, ImmunOs has named four new members of its board: Markus Hosang of BioMedPartners, Michael Baran of Pfizer, Reinhard Ambros, former head of the Novartis Venture Fund, and Daniel Vasella, former chairman and CEO of Novartis.
“Recent advances in the understanding of the innate immune system’s role in cancer provide a unique opportunity for ImmunOs Therapeutics and our partners,” commented Sean R. Smith, CEO of ImmunOs Therapeutics, in the statement.
ImmunOs Therapeutics AG is a spinoff from the University of Zurich (UZH) and the University of Basel, and is headquartered in the Bio-Technopark Schlieren-Zürich.
More news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space